Cellink AB to take-over Discover Echo Inc
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Rheincell set to be acquired by Catalent
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
Data protection rules may block medical progress
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies bags 20m in Series A financing
NeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma expands its ATMP development facilities
Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
BioverSys AG bags $15m CARB-X funding
CARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.
Lonza expands EU production capacity for Moderna vaccine
Lonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
EU approves Biontech/Pfizer vaccine for adolescents
The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Bio and Bluerock ink Regmed collaboration
Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
Pieris in $1.4bn deal with Roche
German-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
|
|
|
||